Indaptus Therapeutics (NASDAQ:INDP) Stock Price Up 15.3% – Still a Buy?

Shares of Indaptus Therapeutics, Inc. (NASDAQ:INDP) rose 15.3% during mid-day trading on Thursday . The stock traded as high as $3.65 and last traded at $3.7010. Approximately 462,507 shares traded hands during mid-day trading, a decline of 26% from the average session volume of 623,553 shares. The stock had previously closed at $3.21.

Analyst Upgrades and Downgrades

Several analysts have recently commented on INDP shares. Wall Street Zen upgraded shares of Indaptus Therapeutics to a “hold” rating in a research note on Saturday, June 27th. Weiss Ratings restated a “sell (e+)” rating on shares of Indaptus Therapeutics in a research report on Friday, July 17th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Indaptus Therapeutics Stock Up 15.9%

The stock has a fifty day moving average price of $1.78 and a two-hundred day moving average price of $2.16. The company has a market capitalization of $495.79 million, a price-to-earnings ratio of -0.59 and a beta of 1.17.

Indaptus Therapeutics (NASDAQ:INDP) last announced its earnings results on Thursday, August 13th. The company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($1.57) by $1.55.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer and other serious diseases. The company’s approach is designed to activate the body’s innate and adaptive immune systems to generate a broad, potentially durable therapeutic response.

Indaptus’s lead platform, Decoy20, is based on an engineered formulation of inactivated bacteria intended to stimulate immune cells without causing an active infection. The company has been evaluating Decoy20 as a treatment for advanced solid tumors, including in combination with other cancer therapies.